Meet Tivdak: The “Smart Delivery” Cancer Drug With a Very Real Eye-Care To-Do List

Tivdak (tisotumab vedotin-tftv) is a prescription cancer medicine used in adults with recurrent or metastatic
cervical cancer that has progressed on or after chemotherapy. It’s given as an IV infusion in a clinic, and it’s
best known for two things: (1) being an antibody-drug conjugate (ADC)think “targeted delivery with a payload,”
and (2) having a boxed warning for serious eye (ocular) toxicity, which is why eye drops and eye checks are not
optional “nice-to-haves.” They’re part of the plan.

In April 2024, the U.S. FDA granted traditional approval for tisotumab vedotin-tftv for this cervical cancer
indication (it had previously been under accelerated approval). In other words: this isn’t a new kid anymoreit’s
a fully approved option in its lane, with clearly defined monitoring and safety steps.

What Tivdak Is Used For

Approved use

Tivdak is indicated for adult patients with recurrent or metastatic cervical cancer whose disease
has progressed on or after chemotherapy. “Recurrent” means it returned after treatment; “metastatic”
means it has spread to other parts of the body.

Off-label use?

You might see tisotumab vedotin discussed in research for other cancers, but approved use can differ from what’s
being studied. If you see “promising trial results,” treat that as a conversation starter with your oncologistnot
a green light to assume it’s appropriate for you.

How Tivdak Works (In Plain English)

Tivdak is a tissue factor–directed antibody-drug conjugate. The antibody part is designed to bind
to a protein called tissue factor, which can be present on some cancer cells. Attached to that antibody
is a potent anti-cancer “payload” called monomethyl auristatin E (MMAE), a microtubule inhibitor.

Here’s the simplified storyline: the antibody helps the drug home in, the complex is taken into the cell, and the
MMAE payload interferes with cell divisionaiming to slow or stop tumor growth. This “guided delivery” concept is
why ADCs get described as a blend of targeted therapy and chemotherapy energyjust packaged differently.

Dosing & Administration (What “Getting Tivdak” Actually Looks Like)

Dose schedule

Tivdak is administered as an intravenous infusion over 30 minutes, typically
once every 3 weeks, continuing until disease progression or unacceptable toxicity.

Standard dose

The recommended dose is 2 mg/kg (maximum 200 mg for patients weighing
100 kg or more).

Do’s and don’ts during administration

• Infusion onlynot an IV push or bolus.
• Don’t mix Tivdak with other medications in the same infusion line.
• Clinics commonly use an in-line filter, per preparation and administration instructions.

Dose reductions (if side effects force the issue)

If significant adverse reactions occur, clinicians may withhold, reduce, or discontinue Tivdak based on severity.
A common dose-reduction sequence is:

If a patient can’t tolerate 0.9 mg/kg, treatment may be discontinued.

Boxed Warning & Key Warnings: The “Read This Twice” Section

Boxed Warning: Ocular (Eye) Toxicity

Tivdak can cause severe ocular toxicities that may lead to changes in vision, including
severe vision loss, and corneal injury (including ulceration). Because of this risk, eye checks and
an eye-care routine (drops + cooling) are built into treatment.

Other important warnings

• Peripheral neuropathy: Numbness, tingling, or painoften in hands/feetmay occur and can worsen
  with ongoing treatment.
• Hemorrhage (bleeding): Tivdak may increase bleeding risk; nosebleeds are commonly reported, but
  more serious bleeding can occur.
• Pneumonitis: Inflammation in the lungs can be serious. New or worsening cough, shortness of breath,
  or chest symptoms should be reported promptly.
• Severe cutaneous (skin) reactions: Rare but serious skin reactions can occur and may require stopping
  treatment.
• Embryo-fetal toxicity: Tivdak can harm an unborn baby. Effective contraception and pregnancy
  counseling are important parts of care planning.

When to contact your care team urgently

Call your oncology team right away if you have new or worsening vision changes, eye pain/redness, sudden breathing
problems, significant bleeding, or severe rash/skin symptoms. The goal is not to “tough it out”it’s to catch
problems early while they’re more manageable.

Required Eye Care Plan (Yes, It’s a Whole ThingHere’s How to Make It Less Annoying)

Tivdak’s eye-care plan is designed to lower the risk of ocular adverse reactions. Your team may tailor details, but
the core elements typically include:

1) Eye exams (ophthalmic exams)

Expect eye evaluations before starting Tivdak and periodically during treatment. These exams often include visual
acuity testing and a slit-lamp exam of the front of the eye.

2) Steroid eye drops

Patients are commonly instructed to use a steroid eye drop in each eye before infusion and to continue it multiple
times daily for a few days after treatment (your team will specify the exact product and schedule).

3) Vasoconstrictor eye drops (right before infusion)

A vasoconstrictor drop is typically administered immediately prior to the infusion.

4) Cold packs during infusion

Cooling eye pads/cold packs are used during the infusion to help reduce exposure of the eyes’ surface tissues to
circulating drug.

5) Lubricating (artificial tear) drops

Lubricating drops are usually recommended throughout treatment and for a period after the last dose to help manage
dryness and irritation.

6) Contact lenses: usually “not right now”

Patients are commonly advised to avoid contact lenses during treatment unless an eye specialist specifically clears
them.

Pro tip

Put your eye-drop schedule in your phone as recurring reminders. Tivdak doesn’t care if you’re “not a routine person.”
Tivdak wants what Tivdak wants.

Side Effects

Side effects vary from person to person. Some are annoying-but-manageable; others can be serious and require dose
delays or discontinuation. Your care team will monitor labs and symptoms closely.

Common side effects (often reported)

• Low hemoglobin (anemia)
• Peripheral neuropathy (numbness/tingling)
• Eye-related reactions (conjunctival irritation/redness, dry eye, keratitis)
• Nausea
• Fatigue
• Nosebleeds (epistaxis)
• Hair loss (alopecia)
• Elevated liver enzymes (AST/ALT)
• Bleeding-related events

Less common but serious side effects

• Severe ocular injury with vision changes
• Significant bleeding
• Lung inflammation (pneumonitis)
• Severe skin reactions
• Infusion reactions (your team will watch during and after infusion)

Practical symptom tracking

If you’re receiving Tivdak, it helps to track: vision changes (even subtle), eye discomfort, new tingling/numbness,
bleeding episodes (nosebleeds frequency matters), breathing symptoms, and fatigue patterns. The more specific you
can be“started 2 days after infusion, lasts 3 days, worse in the evening”the easier it is for your team to act.

Drug Interactions (and Why Your Medication List Matters)

Tivdak’s payload component (MMAE) is metabolized through pathways that can be influenced by other drugs. The big
interaction category to know is strong CYP3A4 inhibitors, which may increase MMAE exposure and
potentially raise the risk of adverse reactions. Your clinician may recommend closer monitoring if you need one of
these medications.

Examples of strong CYP3A4 inhibitors (not a complete list)

• Some azole antifungals (e.g., ketoconazole, itraconazole)
• Some antibiotics (e.g., clarithromycin)
• Some antivirals used for HIV/HCV (certain regimens)

What about CYP3A4 inducers?

Strong CYP3A4 inducers (like rifampin) can decrease MMAE exposure with related drugs. Even if a label emphasizes
inhibitors for monitoring, your oncology pharmacist still wants to know about inducers because they may affect
exposure and effectiveness considerations.

Don’t forget OTC products and supplements

“It’s just a supplement” is not a magic spell. Always disclose over-the-counter meds, vitamins, and herbals. Your
team is not trying to take away your turmeric era; they’re trying to prevent avoidable side effects.

Warnings for Specific Populations

Pregnancy and contraception

Tivdak can cause fetal harm. People who can become pregnant (and those with partners who can become pregnant) should
discuss contraception and timing with their oncology team before starting treatment.

Breastfeeding

Breastfeeding is generally not recommended during treatment and for a period after the last dose. Your provider can
give the exact timeframe based on current guidance.

Hepatic impairment (liver problems)

Moderate to severe hepatic impairment may increase MMAE exposure and the risk of adverse reactions. Clinicians may
avoid Tivdak in these cases or proceed with heightened caution depending on overall circumstances.

Pictures: What Tivdak “Looks Like” and What You’ll See on Treatment Day

Online drug monographs often include “pictures.” For Tivdak, the most useful visuals are usually not glamour shots
of a vialthey’re practical images that help you recognize the process and the required eye-care routine.

FAQ

Is Tivdak chemotherapy?

Tivdak is an ADC, which combines a targeted antibody with a cytotoxic payload (MMAE). Many people describe it as
“targeted delivery of a chemo-like payload.” The classification may differ by context, but the side-effect
monitoring is very real either way.

Do I really need the eye drops if my eyes feel fine?

Yesbecause the eye-care plan is preventative. Ocular side effects can develop even if you start with no symptoms.
The goal is to reduce risk before trouble starts, not after.

What should I bring to infusion appointments?

Many clinics recommend bringing your prescribed eye drops (if you self-administer any around treatment time),
sunglasses (light sensitivity happens), and a list of symptoms and meds since the last visit. Your team will have a
systemask what they prefer.

Real-World Experiences (About ): What Tivdak Treatment Can Feel Like

People often want “the real story” beyond the official warnings: What’s it actually like to be on Tivdak? Experiences
vary, but a few themes come up repeatedly in patient education materials and clinic conversations.

First, many patients say the eye routine is the most memorable partnot necessarily because it’s painful,
but because it’s structured and persistent. Even if the infusion itself feels straightforward, the drops can make
treatment feel like a mini project: “Before infusion, during infusion, for days after, and keep lubricating drops
handy.” Some people swear by phone alarms. Others keep their drops in a small pouch that lives next to their keys so
they never leave home without them. A surprisingly common moment is realizing you now have opinions about artificial
tears (and that “preservative-free” sounds like a spa trend but is actually practical).

On infusion day, patients often describe the 30-minute infusion as manageable, with the quirky detail of
cold packs on the eyes. The cooling can feel odd at firstlike a beauty treatment you did not ask for
but many people adjust quickly. Some bring a soft hat or hoodie for comfort, and some request extra blankets because
a cool face can make the rest of you feel colder. Nurses and infusion staff frequently become the MVPs here: they
help make sure the eye-care steps happen on schedule and that any early symptoms are flagged.

In the days after treatment, a common pattern is fatigue that can be mild or significant. Patients often
describe it as “my battery drains faster,” rather than a need to sleep 24/7. Planning lighter days after infusion
if possiblecan make life feel less like you’re sprinting through quicksand. Nausea can also show up, and many people
find it easier when they keep small snacks around and follow their team’s anti-nausea plan instead of waiting for
symptoms to escalate.

Another frequent real-world topic is peripheral neuropathy. Some people notice tingling or numbness early,
while others don’t. Patients often learn that the most useful description isn’t “it’s bad,” but “it’s worse at night,”
“it’s affecting buttons and zippers,” or “it’s making me feel unsteady on stairs.” Those details help clinicians decide
whether to pause, reduce dose, or change supportive care.

Finally, many patients say the biggest emotional relief comes from having a team that treats side effects as
actionable data, not personal failure. Reporting eye discomfort or bleeding isn’t being “dramatic”it’s
helping your care team keep you safe and on track. Tivdak can be a meaningful option for the right patient at the
right time, but it works best when the monitoring plan is followed like it’s part of the medicationbecause it is.